CRISPR and Genome Editing

How programmable nucleases, especially RNA-guided CRISPR–Cas systems, make targeted cuts in DNA that let researchers edit genomes with unprecedented ease.

Definition

Genome editing is the targeted alteration of an organism's DNA at chosen sites using programmable nucleases; CRISPR–Cas is an RNA-guided system, derived from bacterial immunity, in which a guide RNA directs the Cas nuclease to a matching DNA sequence to create a double-strand break for editing.

Scope

This topic covers targeted genome editing, centred on CRISPR–Cas. It addresses the bacterial origin of CRISPR as an adaptive immune system, the principle of RNA-guided DNA cleavage by Cas9, how the resulting break is repaired to delete or insert sequence, and a brief contrast with earlier programmable nucleases. It treats the method and its logic; broader cloning, amplification, and sequencing methods are covered in companion topics.

Core questions

• Where does CRISPR come from and what is its natural function?
• How does a guide RNA direct Cas9 to a specific DNA sequence?
• How is the double-strand break used to delete or insert sequence?
• How does CRISPR compare with earlier genome-editing tools?

Key theories

RNA-guided DNA cleavage

Jinek and colleagues showed that the Cas9 nuclease can be programmed by a single guide RNA to cut any matching DNA sequence, turning a bacterial immune system into a versatile, easily targeted editing tool.

Repair-directed editing

The double-strand break created at the target is repaired by the cell's own pathways, so that error-prone end joining disrupts a gene or homology-directed repair introduces a defined change supplied by a template.

Mechanisms

In CRISPR–Cas editing, a guide RNA base-pairs with a target DNA sequence adjacent to a short recognition motif, directing the Cas nuclease to cut both strands at that site. The cell then repairs the break: non-homologous end joining often introduces small insertions or deletions that knock out a gene, while homology-directed repair, given a donor template, installs a precise sequence change. Because specificity is set simply by the guide RNA sequence, the system is far easier to retarget than earlier protein-programmed nucleases.

Clinical relevance

Genome editing is being developed for gene and cell therapies and is a standard research tool, while its use in humans raises significant ethical considerations; presented as significance rather than clinical guidance.

History

Building on the discovery that CRISPR loci form a bacterial adaptive immune system, the 2012 demonstration by Doudna and Charpentier that Cas9 can be programmed with a single guide RNA established CRISPR genome editing, recognised by the 2020 Nobel Prize in Chemistry.

Debates

Human germline editing

Editing heritable cells raises ethical and safety concerns about consent, off-target effects, and equity; the scientific community has called for caution while applications to non-heritable cells advance.

Key figures

• Jennifer Doudna
• Emmanuelle Charpentier

Seminal works

• jinek2012
• watson2013

Frequently asked questions

What does the guide RNA do in CRISPR?

It base-pairs with a matching DNA sequence and directs the Cas nuclease to cut there, so changing the guide changes the target.

How does cutting the DNA result in an edit?

The cell repairs the break; depending on the pathway and any template provided, this either disrupts the gene or introduces a precise intended change.